. 2021 Jan 12;13:22. doi: 10.1186/s13195-020-00767-3

Table 2.

CSF biomarker levels measured by three immunoassay platforms

Groups	CSF biomarker levels, median (95% CI)
Groups	Aβ₄₂	Aβ₄₀	T-tau	P-tau	T-tau/Aβ₄₂	P-tau/Aβ₄₂	Aβ₄₂/Aβ₄₀
Luminex-AlzBio3
CN	573.2 (511.3–600.6)	n.d.	46.1 (42.1–55.4)	16.1 (13.7–18.6)	0.09 (0.08–0.10)	0.03 (0.03–0.03)	n.d.
SCD	520.3 (484.2–570.5)	n.d.	46.0 (41.4–55.6)	16.9 (14.0–20.1)	0.09 (0.08–0.11)	0.03 (0.03–0.04)	n.d.
MCI	411.2 ^a,b (282.8–541.1)	n.d.	48.4 (42.0–63.0)	21.2 (15.1–25.5)	0.12 (0.08–0.18)	0.05 ^a (0.03–0.08)	n.d.
AD	258.9 ^a,b,c (234.0–305.0)	n.d.	81.6 ^a,b,c (67.4–127.2)	32.5 ^a,b (28.9–51.5)	0.36 ^a,b,c (0.24–0.57)	0.14 ^a,b,c (0.12–0.22)	n.d.
INNOTEST
CN	756.7 (583.8–879.8)	6724 (5160–9070)	195.0 (156.1–239.7)	38.5 (35.0–49.7)	0.26 (0.23–0.32)	0.05 (0.05–0.07)	0.11 (0.09–0.12)
SCD	794.9 (642.0–950.7)	7405 (6388–9565)	199.5 (145.6–270.4)	43.8 (34.6–50.1)	0.26 (0.20–0.31)	0.05 (0.04–0.06)	0.10 (0.09–0.12)
MCI	565.1 ^b (390.4–734.9)	7158 (5551–8164)	207.7 (156.3–291.5)	46.4 (34.1–53.6)	0.31 (0.23–0.66)	0.07 (0.05–0.12)	0.09 (0.06–0.12)
AD	407.5 ^a,b,c (328.1–412.0)	6504 (5664–8218)	548.0 ^a,b,c (389.4–832.0)	72.5 ^a,b,c (56.9–113.8)	1.55 ^a,b,c (0.95–2.71)	0.24 ^a,b,c (0.14–0.38)	0.05 ^a,b,c (0.05–0.07)
Lumipulse
CN	1104 (850.2–1340)	12,521 (10583–14,851)	224.0 (176.0–254.8)	28.7 (22.9–33.5)	0.20 (0.16–0.24)	0.03 (0.02–0.03)	0.09 (0.08–0.09)
SCD	958.9 (763.9–1148)	12,098 (10655–13,956)	221.5 (174.8–284.5)	28.3 (25.0–37.6)	0.21 (0.17–0.27)	0.03 (0.03–0.03)	0.09 (0.08–0.09)
MCI	651.4 ^a,b (465.1–884.6)	10,686 (9385–12,829)	253.0 (192.0–342.0)	35.0 (24.7–52.1)	0.29 ^a (0.22–0.83)	0.04 ^a,b (0.03–0.12)	0.07 ^a,b (0.04–0.09)
AD	497.9 ^a,b (407.6–527.7)	11,735 (9603–12,385)	544.0 ^a,b,c (448.0–735.8)	89.8 ^a,b,c (66.3–115.7)	1.35 ^a,b,c (4.03–1.63)	0.22 ^a,b,c (0.15–0.26)	0.04 ^a,b,c (0.04–0.05)

^aP < 0.05 versus CN; ^bP < 0.05 versus SCD; ^cP < 0.05 versus MCI by Dunn’s multiple comparison following Kruskal–Wallis test